Type-1 Diabetes Treatment Market Global Analysis, Size, Share, Trends, And Forecast 2019 to 2025

The market for type-1 diabetes treatment is growing rapidly due to the increased number of cases caused by lifestyle changes and a burgeoning population.

North America has a very large patient pool afflicted with type-1 diabetes due to a combination of sedentary lifestyles and genetic and environmental factors. The prevalence of the disease shows no signs of abating and is forecast to increase as several more individuals are diagnosed with type-1 diabetes.

Asia-Pacific has the largest population in the world, with a growing geriatric population and increasing incidence of obesity. As the elderly and the obese are highly susceptible to type-1 diabetes, Asia-Pacific is soon slated to become the market for type-1 diabetes medication.

Registering a CAGR of 7.9%, the global Type-1 Diabetes Treatment Market is expected to touch USD 9.6 billion by 2025.

KEY PLAYERS

• Astellas Pharma (Japan)
• Eli Lilly (US)
• Merck (US)
• Novo Nordisk (Denmark)
• Sanofi (France)
• AstraZeneca (UK)
• Boehringer Ingelheim GmbH (Germany)
• Novartis (Switzerland)
• Pfizer Inc. (US)
• Abbott Laboratories (US)
• Mannkind Corporation (US)
• Braun Melsungen AG (Germany)
• Macrogenics, Inc. (US)
• DiaVacs, Inc. (US)
• Biodel, Inc. (US)

SEGMENTATION

By Product

1. Rapid-Acting Insulin: The largest and fastest-growing segment.
2. Short-Acting Insulin
3. Medium-Acting Insulin
4. Long-Acting Insulin
5. Others

By End User

1. Hospitals and Clinics: Currently the largest and fastest-growing segment.
2. Specialty Centers
3. Others

By Region

1. Americas
2. Europe
3. Asia-Pacific
4. Middle East & Africa

Browse More Information @ https://www.marketresearchfuture.com/reports/type-1-diabetes-treatment-market-8199

REGIONAL ANALYSIS

Americas: Currently, the largest, the market in the Americas has been divided into North and Latin America. The North American market is projected to be larger during the review period due to the high prevalence of the diseased caused by the adoption of sedentary lifestyles and genetic and environmental factors.

Europe: A growing geriatric population and an excellent healthcare system are the driving factors for the growth of the European type-1 diabetes treatment market. Moreover, in Scandinavia, the prevalence of the disease is disproportionately high.

Asia-Pacific: Asia-Pacific is expected to be the fastest-growing regional market during the forecast period. A growing population base, an increasing geriatric population, and lifestyle changes have exacerbated the onset of type-1 diabetes, which is driving market growth.

Middle East & Africa: Currently the smallest, the regional market is expected to grow at a moderate pace. The Middle East has a disproportionality large patient pool afflicted with type-1 diabetes, which is propelling the growth of the market.